Atomoxetine and bupropion interaction

Abstract

In addition to its approved use for the treatment of patients with attention‐deficit hyperactivity disorder (ADHD), the selective norepinephrine reuptake inhibitor atomoxetine is sometimes used off‐label as an adjunctive therapy for patients with major depressive disorder. Bupropion, a norepinephrine/dopamine reuptake inhibitor approved for the treatment of depression, is also used off‐label for ADHD. Bupropion is a potent inhibitor of CYP2D6, the cytochrome P‐450 isoenzyme responsible for mediating the primary hydroxylation pathway of atomoxetine to its active metabolite 4‐hydroxy‐atomoxetine.